Rallybio Corporation
RLYB
$0.535
$0.0715.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 212.00K | 38.00K | 299.00K | 299.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 212.00K | 38.00K | 299.00K | 299.00K | -- |
| Cost of Revenue | 5.73M | 7.39M | 8.24M | 12.95M | 10.94M |
| Gross Profit | -5.51M | -7.35M | -7.94M | -12.65M | -10.94M |
| SG&A Expenses | 4.16M | 4.26M | 4.13M | 4.39M | 5.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.88M | 11.65M | 12.37M | 17.33M | 16.49M |
| Operating Income | -9.67M | -11.61M | -12.07M | -17.04M | -16.49M |
| Income Before Tax | -9.44M | -11.04M | -11.47M | -16.24M | -19.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.44M | -11.04M | -11.47M | -16.24M | -19.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.44M | -11.04M | -11.47M | -16.24M | -19.03M |
| EBIT | -9.67M | -11.61M | -12.07M | -17.04M | -16.49M |
| EBITDA | -9.64M | -11.58M | -12.03M | -17.00M | -16.45M |
| EPS Basic | -0.21 | -0.25 | -0.26 | -0.37 | -0.47 |
| Normalized Basic EPS | -0.13 | -0.15 | -0.16 | -0.23 | -0.24 |
| EPS Diluted | -0.21 | -0.25 | -0.26 | -0.37 | -0.47 |
| Normalized Diluted EPS | -0.13 | -0.15 | -0.16 | -0.23 | -0.24 |
| Average Basic Shares Outstanding | 44.77M | 44.66M | 44.59M | 44.13M | 40.77M |
| Average Diluted Shares Outstanding | 44.77M | 44.66M | 44.59M | 44.13M | 40.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |